Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma - PubMed (original) (raw)
Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma
J A Ajani et al. J Clin Oncol. 1999 Aug.
Abstract
Purpose: Patients with local-regional gastric carcinoma have a low rate of curative resection (R0) because of the advanced stage at diagnosis and suboptimal clinical staging. This study was designed to improve clinical staging with the use of laparoscopy and endoscopic ultrasonography (EUS) and to improve R0 resection rates and tolerance by delivering all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma.
Patients and methods: All patients with histologic proof of localized adenocarcinoma of the stomach underwent a staging laparoscopy before registration. EUS was performed when feasible. The intention was to administer up to five courses of preoperative chemotherapy consisting of fluorouracil (500 mg/m(2)/d as a continuous infusion on days 1 through 5 and as a bolus on days 12 and 19), interferon alfa-2b (3 million units subcutaneously three times a week for 3 weeks), and cisplatin (15 mg/m(2)/d as a bolus on days 1 through 5). After chemotherapy, surgery was attempted to remove the primary and regional lymph nodes. Clinical response and EUS staging were correlated with surgical pathology. The feasibility of this approach, resection rates, patient survival, and patterns of failure also were assessed.
Results: All 30 patients enrolled were assessed for toxicity, response, and survival. Nineteen men and 11 women were enrolled. The median number of courses delivered per patient was three (range, one to five courses). Fourteen patients (47%) received all five preoperative courses of chemotherapy. The overall clinical response rate was 34%. Twenty-nine patients (97%) underwent attempted resection. Twenty-five (83%) had an R0 resection. Two patients (7%) had no evidence of carcinoma in the surgical specimen, and three had only microscopic carcinoma (>/= 90% necrosis). Posttreatment EUS findings did not correlate well with surgical pathology. The median duration of follow-up was 30 months (range, 5 months to 65+ months). The median survival time for 30 patients, calculated by the Kaplan-Meier method, was 30 months (range, 5 months to 65+ months). There were no cases of grade 4 toxicity.
Conclusion: It is feasible to administer prolonged preoperative therapy in patients with potentially resectable gastric carcinoma. Enhanced staging with laparoscopy and EUS helped in proper selection of patients and better characterization of the stage.
Similar articles
- Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, Sugarbaker DJ, Dumas P, Gray C, Vena DA, et al. Ajani JA, et al. J Natl Cancer Inst. 1993 Nov 17;85(22):1839-44. doi: 10.1093/jnci/85.22.1839. J Natl Cancer Inst. 1993. PMID: 8230264 - A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA. Ajani JA, et al. Cancer. 2001 Jul 15;92(2):279-86. doi: 10.1002/1097-0142(20010715)92:2<279::aid-cncr1320>3.0.co;2-2. Cancer. 2001. PMID: 11466680 Clinical Trial. - Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, Kollmannsberger C, Siewert JR, Fink U. Ott K, et al. Gastric Cancer. 2003;6(3):159-67. doi: 10.1007/s10120-003-0245-4. Gastric Cancer. 2003. PMID: 14520529 Clinical Trial. - Neoadjuvant and adjuvant chemotherapy of locally advanced stomach cancer.
Morant R. Morant R. Onkologie. 2001 Apr;24(2):116-21. doi: 10.1159/000050297. Onkologie. 2001. PMID: 11441289 Review.
Cited by
- Adenocarcinoma of the stomach: a review.
McLoughlin JM. McLoughlin JM. Proc (Bayl Univ Med Cent). 2004 Oct;17(4):391-9. doi: 10.1080/08998280.2004.11928001. Proc (Bayl Univ Med Cent). 2004. PMID: 16200126 Free PMC article. No abstract available. - Adjuvant and preoperative chemotherapy for gastric cancer.
Yao JC, Ajani JA. Yao JC, et al. Curr Oncol Rep. 2002 May;4(3):222-8. doi: 10.1007/s11912-002-0019-x. Curr Oncol Rep. 2002. PMID: 11937012 Review. - Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.
Newman E, Marcus SG, Potmesil M, Sewak S, Yee H, Sorich J, Hayek M, Muggia F, Hochster H. Newman E, et al. J Gastrointest Surg. 2002 Mar-Apr;6(2):212-23; discussion 223. doi: 10.1016/s1091-255x(01)00054-3. J Gastrointest Surg. 2002. PMID: 11992807 Clinical Trial. - Interpretation of Tumor Response Grade following Preoperative Therapy for Gastric Cancer: An Overview.
Tsagkalidis V, Blaszczyk MB, In H. Tsagkalidis V, et al. Cancers (Basel). 2023 Jul 18;15(14):3662. doi: 10.3390/cancers15143662. Cancers (Basel). 2023. PMID: 37509323 Free PMC article. Review. - A Shortcut from Genome to Drug: The Employment of Bioinformatic Tools to Find New Targets for Gastric Cancer Treatment.
Brito DMS, Lima OG, Mesquita FP, da Silva EL, de Moraes MEA, Burbano RMR, Montenegro RC, Souza PFN. Brito DMS, et al. Pharmaceutics. 2023 Sep 12;15(9):2303. doi: 10.3390/pharmaceutics15092303. Pharmaceutics. 2023. PMID: 37765273 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical